Point-of-care Molecular Diagnostics Market is predicted to muster a total revenue of around US$ 4 Billion by 2026

[321 Pages Report] Per the point-of-care molecular diagnostics market survey by Future Market Insights (FMI), the market is forecasted to move forward at an average pace and register a CAGR of 8% from 2022 to 2032.

Many current POC diagnostics are based on lateral flow immunoassay technology, and these instruments use antibodies to detect the presence of an analyte, such as cancer biomarkers, in a short period and thus, having the effect of spurring the point-of-care molecular diagnostics market growth to a large extent.

As per the point-of-care molecular diagnostics market report, the demand for point-of-care molecular diagnostics is on a surge owing to the growing trend toward preventive medicine. This is considered to shape the point-of-care molecular diagnostics future trends to a large extent.

According to United Nations data, the number of older adults has steadily increased for decades. As a result of this demographic shift, the prevalence of various chronic diseases is rising, thereby facilitating the adoption of point-of-care molecular diagnostics devices.

The study finds that current cancer diagnostic methods are invasive (for example, cystoscopy, which involves inserting a hollow tube/cystoscope installed with a lens into the urethra and bladder to diagnose cancer). However, less invasive methods, such as point-of-care molecular tests, can be available for point-of-care cancer diagnostics, broadening the point-of-care molecular diagnostics opportunities.

Though most of the industries’ overall sales of molecular diagnostics dwindled steeply due to the COVID-19 pandemic and the use of molecular diagnostic methods for COVID-19 testing, it had a positive impact on the point-of-care molecular diagnostics market size.

As countries gradually slacken their restrictions on movement, there is a resurgence in testing numbers. Aside from vaccines and therapeutic drugs, there is an increasing demand for the development of more precise and simple testing technologies and the expansion of testing structures.

Thus, point-of-care molecular diagnostics companies have made strategic decisions to introduce POC rapid tests, maintain revenue, and mitigate COVID-19’s impact on their operational capabilities. This point-of-care molecular diagnostics market trend is expected to continue in the coming years.

Aside from cancer in the elderly, respiratory diseases in children and adults are becoming one of the top five causes of death. However, as per Pfizer, there are currently no RSV immunization options available, although many vaccines are still in clinical trials.

People are dying due to this since they are unaware of the available treatment. Thus, the prevalence of point-of-care molecular diagnostic tests plays a vital role in quick analysis and, as a result, in providing patients with immediate treatment.

The point-of-care molecular diagnostics market is predicted to muster a total revenue of around US$ 4 Bn by 2026 on account of the abovementioned factors.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-14279

Key Takeaways

  • The assays and kits segment is expected to account for a significant chunk of the POC molecular diagnostics market based on the product type. The market growth of this segment is being driven by the widespread purchase of these products’ POC diagnostic devices as a result of their frequent usage.
  • The RT-PCR segment is expected to dominate the point-of-care molecular diagnostics market in terms of technology, owing to the increasing use of RT-PCR in proteomics, genomics, and COVID-19 testing and the availability of portable, easy-to-use POC devices.
  • The respiratory diseases segment is projected to lead the POC molecular diagnostics market on account of the shift of concentration by key players on various strategies for developing advanced point-of-care diagnostics devices.
  • By end-use, the hospital bedside segment is expected to witness the most significant point-of-care molecular diagnostics market share due to the rising adoption of advanced instruments in these settings and rapid investments in hospital infrastructure by the public and private sectors in emerging countries.
  • The Asia Pacific region is expected to proliferate due to the expansion of key market players, a lack of sophisticated central laboratory point-of-care molecular testing services, and the potential cost-effectiveness of POC molecular diagnosis.

“The North American market is expected to be at the forefront of the point-of-care molecular diagnostics market, attributable to the United States’ emerging trends in point-of-care molecular diagnostics market such as well-organized health-care system. In addition, the system promotes research and development. These policies encourage foreign players to enter the United States and the North American market. As a result, many global market players are present in this region, and the market is projected to flourish as high demand is met by the presence of global players in the region.” opines an FMI researcher.

Competitive Landscape

The top point-of-care diagnostics companies are developing most point-of-care molecular diagnostic tests and have established their market position by investing more in research and developing a better distribution system.

The entry of new players challenges the semi-consolidated market and may result in intense competition during the forecast period.

Furthermore, due to increased awareness, the Asia-Pacific region is seeing the emergence of some minor players, which aided the point-of-care molecular diagnostics market growth.

LLC. (US), Danaher Corporation (US), Alere Inc. (US), Quidel Corporation (US), Biocartis Group NV (Belgium), bioMérieux SA (France), Thermo Fisher Scientific (US), Mesa Biotech Inc. (US), F. Hoffmann-La Roche Ltd., and Meridian Bioscience Inc. (US) are the critical point-of-care diagnostic companies profiled in the global POC molecular diagnostics market.

Recent developments in the point-of-care molecular diagnostics market are as follows:

  • The World Health Organization (WHO), Africa Centers for Disease Control and Prevention (Africa CDC), the Bill & Melinda Gates Foundation, the Clinton Health Access Initiative (CHAI), the Foundation for Innovative New Diagnostics (FIND), and the Global Fund constituted a global partnership. Today, the organization announced the launch of the COVID-19 rapid test in low and middle-income countries.
  • Mylab Discovery Solutions has collaborated with Hemex Health, the United States company, to develop next-generation diagnostic solutions for coronavirus and another point-of-care diagnostic testing.

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-14279

Point-of-care Molecular Diagnostics Market Key Segments

By Product & Service:

  • Assays & kits
  • Instruments & Analyzers
  • Software & Services

By Technology:

  • RT-PCR
  • Other technologies

By Application:

  • Respiratory Diseases
  • Sexually Transmitted Diseases
  • Hospital-acquired Infections
  • Cancer
  • Hepatitis
  • Gastrointestinal Disorders
  • Other Applications

By End User:

  • Physicians’ Offices
  • Hospitals & ICUs
  • Research Institutes
  • Other End Users

Related Reports :

FMI’ analysis expects the surgical tourniquets market to grow at ~8% CAGR through to 2029, driven a surge in the number of trauma cases over the years lined with rising demand for effective device to stop arterial bleeding during surgical procedures. Analysts also expect that automatic machines and robotic technologies are likely to bring a paradigm shift in operative procedures, which should push the manufacturers to innovate their products and develop strategies to attract and retain a new segment of customers.

Worldwide sales of surgical tourniquets will increase by 7.5% year-over-year to reach ~US$ 381 million in 2019, up from ~US$ 355 million in 2018, according to the latest research from Future Market Insights (FMI).

In an attempt to reduce the risks associated with higher tourniquet pressures, manufacturers are placing their bets on products innovations and introduction of novel features such as automatic pressure control, audiovisual alarms, digital displays, and easy-to-use user interface.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-2254

Surgical tourniquets have long been reliable to establish a bloodless field of operation for surgeons while maintaining a high level of safety for patients. However, the risk of surgical-site infections as well as tourniquet-related injuries, particularly due to the application of high pressures and high pressure gradients to the patient, remains a potential threat to the market growth.

Sales of Tourniquet Cuffs to Ramp up in 2019

According to the FMI analysts, tourniquet cuffs have been a vital part of the modern computer-assisted tourniquet system, which accounted for ~77% of total market revenue in 2018. While the inflatable disposable cuffs represented more than half of the total tourniquet cuff sales in 2018, the consumption of inflatable reusable cuffs is likely to increase 7.6% y-o-y in 2019.

“In terms of tourniquet systems, dual channel systems will continue to represent a relatively high share as compared to single channel systems, in the view of enabling bi-lateral procedures or simultaneous surgeries of both upper and lower extremity,” the FMI analyst said.

The consumption of surgical tourniquets for knee arthroplasty accounted for ~31% sales in 2018, while increasing application in amputation of limbs and trauma cases is likely to result in increased market share in the future.

“Recent advancements in reverse shoulder arthroplasty along with the introduction of ‘personalized’ tourniquet systems that allow the use of variable contour design and cuffs for specific patients will open new avenues of growth for the market players,” said the FMI analyst.

Hospitals Capture Significant Share, North America in the Vanguard

In 2018, surgical tourniquets worth ~US$ 176 million were sold in hospitals; according to the FMI analysts, growing number of hospitals, especially in developing countries, and greater awareness of advanced medical devices will continue to drive the consumption of surgical tourniquets in hospitals.

Rapid adoption of ‘value-based’ model in health care settings have led to a surge in the number of ambulatory surgical centers and specialized clinics, thereby paving a new way of growth for the surgical tourniquets market.

The FMI analyst forecasts that North America will continue to remain at the forefront of surgical tourniquets market, representing 30% share in 2018. While North America is likely to be neck-and-neck with Europe to lead the market in future, manufacturers are tapping into new opportunities in developing countries in Asia Pacific.

The surgical tourniquets market shows a fair level of fragmentation, with two prominent players including Zimmer Biomet and Stryker Corporation accounting for more than one-third of the total revenue share. Exploring unmet needs in developing regions and expanding their distribution through collaboration and acquisitions of local and regional manufacturers remain key focal points of the market players.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-2254

Key Segment

By Product Type

  • Tourniquet Systems
    • Single Channel Systems
    • Dual Channel Systems
  • Tourniquet Cuffs
  • Inflatable Cuffs
    • Disposable Cuffs
    • Reusable Cuffs
  • Non-Inflatable Cuffs
    • Disposable Cuffs
    • Reusable Cuffs

By Application

  • Knee Arthroplasty
  • Amputation of Limbs
  • Plastic Surgeries
  • Trauma Cases

By End User

  • Hospitals
  • Ambulatory Surgical Centers
  • Specialized Clinics

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-2254

By Region

  • North America
  • Europe
  • Latin America
  • South Asia
  • East Asia
  • Oceania
  • Middle East And Africa
  • Emerging Countries

Related Reports : 





About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Leave a comment

Your email address will not be published. Required fields are marked *